Background Intensified multifactorial intervention — withtight glucose regulation and the use of renin–angiotensinsystem blockers, aspirin, and lipid-lowering agents —has been shown to reduce the risk of nonfatal cardiovasculardisease among patients with type 2 diabetes mellitus and microalbuminuria.We evaluated whether this approach would have an effect on therates of death from any cause and from cardiovascular causes.
Methods In the Steno-2 Study, we randomly assigned 160 patientswith type 2 diabetes and persistent microalbuminuria to receiveeither intensive therapy or conventional therapy; the mean treatmentperiod was 7.8 years. Patients were subsequently followed observationallyfor a mean of 5.5 years, until December 31, 2006. The primaryend point at 13.3 years of follow-up was the time to death fromany cause.
Results Twenty-four patients in the intensive-therapy groupdied, as compared with 40 in the conventional-therapy group(hazard ratio, 0.54; 95% confidence interval [CI], 0.32 to 0.89;P=0.02). Intensive therapy was associated with a lower riskof death from cardiovascular causes (hazard ratio, 0.43; 95%CI, 0.19 to 0.94; P=0.04) and of cardiovascular events (hazardratio, 0.41; 95% CI, 0.25 to 0.67; P<0.001). One patientin the intensive-therapy group had progression to end-stagerenal disease, as compared with six patients in the conventional-therapygroup (P=0.04). Fewer patients in the intensive-therapy grouprequired retinal photocoagulation (relative risk, 0.45; 95%CI, 0.23 to 0.86; P=0.02). Few major side effects were reported.
Conclusions In at-risk patients with type 2 diabetes, intensiveintervention with multiple drug combinations and behavior modificationhad sustained beneficial effects with respect to vascular complicationsand on rates of death from any cause and from cardiovascularcauses. (ClinicalTrials.gov number, NCT00320008
[ClinicalTrials.gov]
.)
Source Information
From the Steno Diabetes Center, Copenhagen (P.G., H.L.-A., O.P.); Department of Ophthalmology, Glostrup University Hospital, Glostrup (H.L.-A.); Department of Medical Endocrinology, Rigshospitalet Copenhagen University Hospital, Copenhagen (H.-H.P.); and Faculty of Health Sciences, University of Aarhus, Aarhus (H.-H.P., O.P.) — all in Denmark.
Address reprint requests to Dr. Pedersen at the Steno Diabetes Center, 2820 Gentofte, Copenhagen, Denmark, or at oluf{at}steno.dk.
Montori, V. M, Malaga, G.
(2008). Intensive glucose control did not prevent important complications in type 2 diabetes. Evid. Based Med.
13: 168-169
[Full Text]
Gulliford, M. C., Charlton, J.
(2008). Is Relative Mortality of Type 2 Diabetes Mellitus Decreasing?. Am J Epidemiol
0: kwn342v1-kwn342
[Abstract][Full Text]
So, W.-Y., Wang, Y., Ng, M. C.Y., Yang, X., Ma, R. C.W., Lam, V., Kong, A. P.S., Tong, P. C.Y., Chan, J. C.N.
(2008). Aldose Reductase Genotypes and Cardiorenal Complications: An 8-year prospective analysis of 1,074 type 2 diabetic patients. Diabetes Care
31: 2148-2153
[Abstract][Full Text]
Bhattacharyya, O. K. MD PhD, Shah, B. R. MD PhD, Booth, G. L. MD MSc
(2008). Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ
179: 920-926
[Full Text]
Home, P.
(2008). Tight control of blood glucose and cardiovascular disease. BMJ
337: a2105-a2105
[Full Text]
Chalmers, J., Cooper, M. E.
(2008). UKPDS and the Legacy Effect. NEJM
359: 1618-1620
[Full Text]
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., Matthews, D. R.
(2008). Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. NEJM
359: 1565-1576
[Abstract][Full Text]
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., Neil, H. A. W.
(2008). 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. NEJM
359: 1577-1589
[Abstract][Full Text]
HOOGWERF, B. J.
(2008). Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD.. Cleveland Clinic Journal of Medicine
75: 729-737
[Abstract][Full Text]
Kidambi, S., Patel, S. B.
(2008). Diabetes Mellitus: Considerations for Dentistry. Journal of the American Dental Association
139: 8S-18S
[Abstract][Full Text]
Cederholm, J., Eeg-Olofsson, K., Eliasson, B., Zethelius, B., Nilsson, P. M., Gudbjornsdottir, S., on behalf of the Swedish National Diabetes Registe,
(2008). Risk Prediction of Cardiovascular Disease in Type 2 Diabetes: A risk equation from the Swedish National Diabetes Register. Diabetes Care
31: 2038-2043
[Abstract][Full Text]
Boekholdt, S. M., de Winter, R. J., Kastelein, J. J.P.
(2008). Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib: Shifting Gears in Cardiovascular Drug Development: Are Antiinflammatory Drugs the Next Frontier?. Circulation
118: 1120-1122
[Full Text]
Bailey, C. J, Day, C.
(2008). Glycaemic memory. British Journal of Diabetes & Vascular Disease
8: 242-247
[Abstract]
Escobar, C., Barrios, V.
(2008). Risk Factors Control in Diabetes: The "Real World" of Clinical Practice. The Diabetes Educator
34: 763-764
[Full Text]
Shah, B. R.
(2008). Utilization of physician services for diabetic patients from ethnic minorities. J Public Health (Oxf)
30: 327-331
[Abstract][Full Text]
Charlton, J., Latinovic, R., Gulliford, M. C.
(2008). Explaining the Decline in Early Mortality in Men and Women With Type 2 Diabetes: A population-based cohort study. Diabetes Care
31: 1761-1766
[Abstract][Full Text]
Triplitt, C., Alvarez, C. A.
(2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr.
21: 177-189
[Abstract][Full Text]
Gouni-Berthold, I., Berthold, H. K., Mantzoros, C. S., Bohm, M., Krone, W.
(2008). Sex Disparities in the Treatment and Control of Cardiovascular Risk Factors in Type 2 Diabetes. Diabetes Care
31: 1389-1391
[Abstract][Full Text]
Dluhy, R. G., McMahon, G. T.
(2008). Intensive Glycemic Control in the ACCORD and ADVANCE Trials. NEJM
358: 2630-2633
[Full Text]
The ADVANCE Collaborative Group,
(2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM
358: 2560-2572
[Abstract][Full Text]
Karalliedde, J., Gnudi, L.
(2008). ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant
23: 1796-1798
[Full Text]
Bloomgarden, Z. T.
(2008). Cardiovascular Disease in Diabetes. Diabetes Care
31: 1260-1266
[Full Text]
Schroeder, S. A., Tayek, J. A., Gaede, P., Parving, H.-H., Pedersen, O.
(2008). Multifactorial Intervention and Mortality in Type 2 Diabetes. NEJM
358: 2292-2293
[Full Text]
Cefalu, W. T., Watson, K.
(2008). Intensive Glycemic Control and Cardiovascular Disease Observations From the ACCORD Study: Now What Can a Clinician Possibly Think?. Diabetes
57: 1163-1165
[Full Text]
Goldfine, A. B., Beckman, J. A.
(2008). Life and Death in Denmark: Lessons About Diabetes and Coronary Heart Disease. Circulation
117: 1914-1917
[Full Text]
Hirsch, I. B.
(2008). Piecing the Puzzle Together: ACCORDing to Whom?. J. Clin. Endocrinol. Metab.
93: 1161-1163
[Full Text]
Home, P.
(2008). Safety of very tight blood glucose control in type 2 diabetes. BMJ
336: 458-459
[Full Text]
(2008). All you need to read in the other general journals. BMJ
336: 354-355
[Full Text]
(2008). Multifactorial Treatment of Type 2 Diabetes with Microalbuminuria. JWatch General
2008: 1-1
[Full Text]